Tech Company M&A Transactions
Protez Pharmaceuticals Acquisition
Protez Pharmaceuticals, based in Malvern, was acquired by Novartis AG. Financial terms set the valuation at $400 million.
Transaction Overview
Company Name
Acquired By
Announced On
6/4/2008
Transaction Type
M&A
Amount
$400,000,000
M&A Terms
Novartis will acquire Protez for up to $400 million in cash, of which $100 million will be paid at closing and of up to $300 million will be paid if certain clinical milestones, regulatory approvals and commercial targets are achieved.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
30 Spring Mill Drive
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Protez Pharmaceuticals discovers and develops new antibiotics for difficult-to-treat infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Cashman
Chief Medical Officer
Clarence Young
Chief Scientific Officer
Luigi Xerri
Co-Founder
Klaus Esser
VP - R & D
Christopher Burns
Browse more venture capital transactions:
Prev: 6/4/2008: Yodlee venture capital transaction
Next: 6/4/2008: FTL Solar venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs